FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019621072> ?p ?o ?g. }

• W2019621072 endingPage "1" @default.
• W2019621072 startingPage "1" @default.
• W2019621072 abstract "Potential role of enzastaurin in the treatment of patients with relapsed or refractory advanced cutaneous T-cell lymphomas: a review Deborah A Katz, Janet MD Plate, Sunita Nathan, Lydia UshaDivision of Hematology and Oncology, Rush University Medical Center, Chicago, IL, USAAbstract: Cutaneous T-cell lymphomas (CTCLs) are rare extranodal non-Hodgkin lymphomas characterized by neoplastic T-lymphocyte accumulation in the skin. The two most common types of CTCLs are mycosis fungoides and the leukemic variant, Sézary syndrome. Prognosis of CTCLs depends on the stage, with a poor prognosis in advanced-stage disease. A number of agents have recently been developed for the treatment of CTCLs: chemotherapeutic agents such as pralatrexate, interferon-alpha, retinoids such as bexarotene, monoclonal antibodies such as alemtuzumab, and histone deacetylase inhibitors such as vorinostat and romidepsin. Nevertheless, there is no cure for CTCLs except for allogeneic stem cell transplant. A promising new drug is enzastaurin. Enzastaurin is a novel serine/threonine kinase inhibitor that binds to protein kinase C-β (PKC-β) and inhibits the phosphoinositide-3 kinase (PI3K)/AKT/phosphatase and tensin homolog (PTEN) signaling pathway. Enzastaurin induces apoptosis and inhibits angiogenesis; it was also shown to suppress growth of CTCL cell lines in vitro. Given its low toxicity, enzastaurin has been tested against both solid tumors and hematologic malignancies. This article is focused on the potential role of enzastaurin in the treatment of CTCLs. A phase II multicenter trial evaluated enzastaurin monotherapy in patients with CTCLs. However, the results from this study were disappointing, demonstrating that enzastaurin had only modest clinical activity. Hence, enzastaurin is not currently developed for treating CTCLs. Potential strategies to improve enzastaurin efficacy against CTCLs are discussed: validation of enzastaurin targets such as PKC-β expression in CTCL lesions and or/blood; measurement of serum vascular endothelial growth factor levels; dose optimization; combining enzastaurin with other antiangiogenic agents, or glycogen synthase kinase inhibitors, or mammalian target of rapamycin (mTOR) inhibitors. Ultimately, developing more potent inhibitors of PKC-β and PI3K/AKT/PTEN/mTOR signaling pathways may be necessary to improve clinical outcomes in CTCLs.Keywords: cutaneous T-cell lymphomas, enzastaurin, PKC-β inhibitors, serine/threonine kinase inhibitors, PI3K/AKT/PTEN pathway" @default.
• W2019621072 created "2016-06-24" @default.
• W2019621072 creator A5002002024 @default.
• W2019621072 creator A5007601060 @default.
• W2019621072 creator A5069120119 @default.
• W2019621072 creator A5088348924 @default.
• W2019621072 date "2012-06-01" @default.
• W2019621072 modified "2023-10-16" @default.
• W2019621072 title "Potential role of enzastaurin in the treatment of patients with relapsed or refractory advanced cutaneous T-cell lymphomas: a review" @default.
• W2019621072 cites W1546496348 @default.
• W2019621072 cites W1603793353 @default.
• W2019621072 cites W1700177965 @default.
• W2019621072 cites W1895474562 @default.
• W2019621072 cites W1901742546 @default.
• W2019621072 cites W1959848155 @default.
• W2019621072 cites W1963656304 @default.
• W2019621072 cites W1965268544 @default.
• W2019621072 cites W1965691258 @default.
• W2019621072 cites W1967160536 @default.
• W2019621072 cites W1972507334 @default.
• W2019621072 cites W1975108670 @default.
• W2019621072 cites W1975479767 @default.
• W2019621072 cites W1977658676 @default.
• W2019621072 cites W1979446681 @default.
• W2019621072 cites W1982347763 @default.
• W2019621072 cites W1990901867 @default.
• W2019621072 cites W1991409470 @default.
• W2019621072 cites W1994947055 @default.
• W2019621072 cites W1997575391 @default.
• W2019621072 cites W2001611608 @default.
• W2019621072 cites W2016373265 @default.
• W2019621072 cites W2021247874 @default.
• W2019621072 cites W2021922201 @default.
• W2019621072 cites W2022514267 @default.
• W2019621072 cites W2024397914 @default.
• W2019621072 cites W2028046471 @default.
• W2019621072 cites W2029854218 @default.
• W2019621072 cites W2032388264 @default.
• W2019621072 cites W2042942970 @default.
• W2019621072 cites W2047770089 @default.
• W2019621072 cites W2053675609 @default.
• W2019621072 cites W2059888019 @default.
• W2019621072 cites W2062141151 @default.
• W2019621072 cites W2066260735 @default.
• W2019621072 cites W2075296106 @default.
• W2019621072 cites W2075870304 @default.
• W2019621072 cites W2078277756 @default.
• W2019621072 cites W2079200036 @default.
• W2019621072 cites W2086572638 @default.
• W2019621072 cites W2096160655 @default.
• W2019621072 cites W2097661119 @default.
• W2019621072 cites W2098301543 @default.
• W2019621072 cites W2104932289 @default.
• W2019621072 cites W2105845113 @default.
• W2019621072 cites W2110957729 @default.
• W2019621072 cites W2112860107 @default.
• W2019621072 cites W2115782311 @default.
• W2019621072 cites W2117692326 @default.
• W2019621072 cites W2120601121 @default.
• W2019621072 cites W2126372596 @default.
• W2019621072 cites W2127268499 @default.
• W2019621072 cites W2129698680 @default.
• W2019621072 cites W2140608535 @default.
• W2019621072 cites W2145155871 @default.
• W2019621072 cites W2148724182 @default.
• W2019621072 cites W2153313108 @default.
• W2019621072 cites W2157453342 @default.
• W2019621072 cites W2158713283 @default.
• W2019621072 cites W2161531371 @default.
• W2019621072 cites W2166319541 @default.
• W2019621072 cites W2167111891 @default.
• W2019621072 cites W2167188058 @default.
• W2019621072 cites W2167312182 @default.
• W2019621072 cites W2167947851 @default.
• W2019621072 cites W2171365282 @default.
• W2019621072 cites W2171881796 @default.
• W2019621072 cites W2172187886 @default.
• W2019621072 cites W2228212766 @default.
• W2019621072 cites W2312173752 @default.
• W2019621072 cites W2413406811 @default.
• W2019621072 cites W2530575980 @default.
• W2019621072 cites W2560600786 @default.
• W2019621072 cites W2582397577 @default.
• W2019621072 doi "https://doi.org/10.2147/odrr.s24757" @default.
• W2019621072 hasPublicationYear "2012" @default.
• W2019621072 type Work @default.
• W2019621072 sameAs 2019621072 @default.
• W2019621072 citedByCount "0" @default.
• W2019621072 crossrefType "journal-article" @default.
• W2019621072 hasAuthorship W2019621072A5002002024 @default.
• W2019621072 hasAuthorship W2019621072A5007601060 @default.
• W2019621072 hasAuthorship W2019621072A5069120119 @default.
• W2019621072 hasAuthorship W2019621072A5088348924 @default.
• W2019621072 hasBestOaLocation W20196210721 @default.
• W2019621072 hasConcept C104317684 @default.
• W2019621072 hasConcept C126322002 @default.
• W2019621072 hasConcept C143998085 @default.
• W2019621072 hasConcept C183713625 @default.

• next